DiaMedica Therapeutics Inc expected to post a loss of 18  cents a share - Earnings Preview

DiaMedica Therapeutics

05/03/2022 24:04

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports 
results on March 8 (estimated). 
    * ​Refinitiv's mean analyst estimate for DiaMedica
Therapeutics
Inc is for a loss of 18 cents per share. For the same quarter
last year, the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $18​, about 86.4% above​ its last closing
price of $2.45. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.21       -0.23      -0.18     Beat    21.1
 Jun. 30 2021  -0.20       -0.21      -0.17     Beat    19.7
 Mar. 31 2021  -0.21       -0.21      -0.19     Beat    10.9​
 Dec. 31 2020  -0.18       -0.17      -0.23     Missed  -36.9
 ​​Sep.        -0.15       -0.15      -0.19     Missed  -29.5
 30 2020                                                
 Jun. 30 2020  -0.16       -0.15      -0.17     Missed  -10.9​
 Mar. 31 2020  -0.27       -0.28      -0.19     Beat    32.9
 Dec. 31 2019  -0.25       -0.25      -0.21     Beat    15.6
 This summary was machine generated March 5 at 00:04 GMT.  All
figures in US dollars  unless otherwise stated